STATE OF THE ART MANAGEMENT OF mCPRC

SUMMIT 2
SINGAPORE

Chairs
Arun Azad, Australia
Ravindran Kanesvaran, Singapore

This educational activity is provided by ESMO and supported by Astellas.

SUNDAY, 24 NOVEMBER 2019
11:00 – 12:30

11:00  Introduction
       Arun Azad, Clayton, Australia

11:05  mCRPC definition and benefits of treatment
       Ravindran Kanesvaran, Singapore

11:15  Optimal first-line treatment in mCRPC after either chemo or ARI in mHSPC
       Cora Sternberg, New York, NY, USA

11:30  Changing treatment algorithms in mCRPC: Role of PARP inhibitors
       Arun Azad, Clayton, Australia

11:45  Is there an optimal sequencing strategy in mCRPC?
       Ben Tran, Melbourne, Australia

12:00  Immunotherapy in mCRPC management
       Arun Azad, Clayton, Australia

12:15  Conclusion and wrap up
       Ravindran Kanesvaran, Singapore